Under the Paperwork Reduction Act of 1995, no persons are required to

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		09886146			
	Filing Date		2001-06-20			
	First Named Inventor	John	E. Brezak			
	Art Unit		2153			
Examiner Name YASII		YASI	IN M BARQADLE			
	Attorney Docket Number		MS1-0896US			

				Attorney L	OCKEL ING	IIIDei	MO1-000000					
				U	S.PATEN	TS			Remove			
Examiner Initial*	r Cite No Patent Number Kind Code¹			Issue Date		Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	5864665	1999-01-26	Tran	Tran							
	2	5875296		1999-02-23	Shi et	al.						
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information	please c	ick the A	Add button.		Add			
<u> </u>			U.S.P	ATENT APP	LICATIO	N PUBL	ICATIONS		Remove			
Examiner Initial*	Cite No	Publication Number	Publication Date		Name of Patentee or Applicant of cited Document			Columns,Lines int Passages of s Appear				
If you wis	h to a	dd additional U.S. Publ		plication cita				d button	Add			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		d Public de4 Date	ation	Name of Patente Applicant of cited Document	or k	Pages,Columns where Relevant Passages or Re Figures Appear	elevant		
	1									1		
If you wis	h to a	dd additional Foreign P						button	Add			
				-PATENT I					Remove			

#### 

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button 

EXAMINER SIGNATURE

Examiner Signature Date Considered Date Consid

See Kini Codes of USPTO Patient Documents at year-USPTO\_GOV or METP 801.04. <sup>2</sup> Enter office that issued the document, by the be-of-time code (WPO Standard ST.3) <sup>2</sup> For dispances patient codem (WPO Standard ST.3) <sup>2</sup> For dispances patient codem (WPO Standard ST.3) <sup>2</sup> For dispances patient codem (WPO Standard ST.7) <sup>3</sup> For dispances patient code (WPO Standard ST.7) <sup>3</sup> For dispance patient code (WPO Standard ST.7) <sup>3</sup> For dispance patient code (WPO Standard ST.7) <sup>3</sup> For possible, <sup>3</sup> Applicant is to place a check mark there it English tanguages the resistation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09886146			
Filing Date		2001-06-20			
First Named Inventor John		E. Brezak			
Art Unit		2153			
Examiner Name YASII		N M BARQADLE			
Attorney Docket Number		MS1-0886US			

36756

#### CERTIFICATION STATEMENT

Please see	37 (	CED .	97	and	1 02	to	make	the	annr	nnris	oto	امه	acti	on/	۱۵	ŀ

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient fortion in a counterpart freeign application, and, to the knowledge of the person spining the certification after making reasonable inquiry, no term of information contained in the information disclosure statement was known to any antividual designated in 37 CFR 156(c) more than there enother joint to the filling of the information disclosure any antividual designated in 37 CFR 156(c) more than there enother joint to the filling of the information disclosure and the contract of the information disclosure and the contract of the information disclosure and the contract of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Frank J. Bozzo

□ None

Name/Print

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.				
Signature	/Frank J. Bozzo, Reg. No. 36756/	Date (YYYY-MM-DD)	2006-06-19	

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandri, V.S. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.2231-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.